SAN DIEGO, Dec. 21, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, at 2:30 p.m. PST. The conference will take place January 8-11, 2018, at the Westin St. Francis Hotel in San Francisco.
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event.
About Arena Pharmaceuticals
Arena Pharmaceuticals is focused on developing novel, small molecule drugs with optimized receptor pharmacology and pharmacokinetics designed to deliver broad clinical utility across several therapeutic areas. Arena's proprietary pipeline includes potentially first- or best-in-class programs. Its most advanced investigational clinical programs are ralinepag (APD811) which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH) and etrasimod (APD334) in Phase 2 evaluation a broad range of autoimmune or immune-mediated conditions. The Company is also evaluating APD371 in Phase 2a evaluation for the treatment of pain associated with Crohn's disease. In addition, Arena has collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (Belviq®), Axovant Sciences (nelotanserin - Phase 2), Boehringer Ingelheim International GmbH (preclinical), and Everest Medicines Limited (Greater China and limited other regions for ralinepag and etrasimod).
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be accompanied by words such as "focused on," "designed to," "will," "may," or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements about the upcoming presentation; and Arena's focus, programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include clinical programs may not proceed at the time or in the manner expected or at all, as well as those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
SOURCE Arena Pharmaceuticals, Inc.
